/
Musculoskeletal
Arthritis
183
Pipeline Programs↗
338
Active Trials↗
186
Companies Involved↗
Arthritis is a highly competitive landscape with 183 programs across 186 companies. The most active players are Suzhou Suncadia Biopharmaceuticals Co., Ltd., XBiotech, Inc.. 26 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical100
Phase 131
Phase 226
Phase 326
Approved
No programs
Analysis
Modality Breakdown
84%
Small molecule
129 of 154 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 154 classified programs, each share of the total. Modality classified for 96% of 183 pipeline programs.
Analysis
Trial Status
1,971
clinical trials
Completed1,267 · 64%
Recruiting176 · 9%
Terminated167 · 8%
Unknown status143 · 7%
Not yet recruiting83 · 4%
Active, not recruiting68 · 3%
Other67 · 3%
Clinical Trials
Trial Activity
1971 trials
Extracorporeal Shock Wave Therapy in Patients With Knee Arthritis
Recruiting·AAzienda Ospedaliero-Universitaria Consorziale Policlinico di Bari·Preclinical·NCT06833372·72 enrolled
Studies on the Natural History and Pathogenesis of Spondyloarthritis
Recruiting·National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)·N/A·NCT01422694·2,000 enrolled
Development of a Multidimensional Prediction Model for the Course and Outcome of Early-Onset Juvenile Idiopathic Arthritis (JIA)
Recruiting·—·N/A·NCT07882667·130 enrolled
Page 1 of 132
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)